PCM
ANTX icon

Prelude Capital Management’s AN2 Therapeutics ANTX Stock Holding History

Prelude Capital Management’s Portfolio ANTX Stock Details ANTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-38,918
Closed -$83.7K – 1262
2024
Q2 		$83.7K Sell
38,918
-1,382
-3% -$3.29K 0.01% 1117
2024
Q1 		$131K Buy
+40,300
New +$439K 0.01% 1175

Other funds holding ANTX

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AI
Acuitas Investments Seattle, Washington $1.41M AUM 48.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Prelude Capital Management's ANTX Position: Q3 2024 in Review

Prelude Capital Management sold out of AN2 Therapeutics (ANTX) in Q3 2024, closing a stake of 38,918 shares — an estimated $83.7K sold.

Prelude Capital Management first reported a position in ANTX in Q1 2024 and held it in 2 quarters. The position peaked at $131K in Q1 2024. 31 funds tracked by Wall St. Rank hold ANTX as of Q3 2024.

  • Prelude Capital Management reported no remaining AN2 Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Prelude Capital Management sold 38,918 AN2 Therapeutics shares in Q3 2024, an estimated $83.7K.
  • Prelude Capital Management first reported a position in AN2 Therapeutics in Q1 2024 and held it in 2 quarters.
  • Prelude Capital Management's AN2 Therapeutics position peaked at $131K in Q1 2024.
  • 31 funds tracked by Wall St. Rank held AN2 Therapeutics as of Q3 2024.

Based on Prelude Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.